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Background: With successful antiretroviral therapy, non-communicable diseases, including malignancies, are
increasingly contributing to morbidity and mortality among HIV-infected persons. The epidemiology of AIDS-defining
cancers (ADCs) and non-AIDS-defining cancers (NADCs) in HIV-infected populations in Brazil has not been well
described. It is not known if cancer trends in HIV-infected populations in Brazil are similar to those of other countries
where antiretroviral therapy is also widely available.
Methods: We performed a retrospective analysis of clinical cohorts at Instituto Nacional de Infectologia Evandro
Chagas (INI) in Rio de Janeiro and Vanderbilt Comprehensive Care Clinic (VCCC) in Nashville from 1998 to 2010.
We used Poisson regression and standardized incidence ratios (SIRs) to examine incidence trends. Clinical and
demographic predictors of ADCs and NADCs were examined using Cox proportional hazards models.
Results: This study included 2,925 patients at INI and 3,927 patients at VCCC. There were 57 ADCs at INI (65% Kaposi
sarcoma), 47 at VCCC (40% Kaposi sarcoma), 45 NADCs at INI, and 82 at VCCC. From 1998 to 2004, incidence of ADCs
remained statistically unchanged at both sites. From 2005 to 2010, ADC incidence decreased in both cohorts (INI
incidence rate ratio per year = 0.74, p < 0.01; VCCC = 0.75, p < 0.01). Overall Kaposi sarcoma incidence was greater at
INI than VCCC (3.0 vs. 1.2 cases per 1,000 person-years, p < 0.01). Incidence of NADCs remained constant throughout
the study period (overall INI incidence 3.6 per 1,000 person-years and VCCC incidence 5.3 per 1,000 person-years).
Compared to general populations, overall risk of NADCs was increased at both sites (INI SIR = 1.4 [95% CI 1.1-1.9] and
VCCC SIR = 1.3 [1.0-1.7]). After non-melanoma skin cancers, the most frequent NADCs were anal cancer at INI (n = 7)
and lung cancer at VCCC (n = 11). In multivariate models, risk of ADC was associated with male sex and
immunosuppression. Risk of NADC was associated with increased age.
Conclusions: In both cohorts, ADCs have decreased over time, though incidence of KS was higher at INI
than VCCC. Rates of NADCs remained constant over time at both sites.
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In the era of highly active antiretroviral therapy (ART),
cancer is an important cause of morbidity and mortality
of individuals living with HIV. Since 1996, in high-
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unless otherwise stated.have increasingly replaced AIDS-defining cancers (ADCs)
as causes of cancer morbidity in HIV-infected populations
[1]. In particular, Hodgkin lymphoma, liver cancer, lung
cancer, anal cancer, and non-melanoma skin cancers occur
at rates in HIV-infected populations above expected in
general populations [2-8].
Cancers occurring in HIV-infected populations in low-
and middle-income countries have not been as well
described. Despite increasing availability of ART,
ADCs continue to account for substantial morbidityl. This is an Open Access article distributed under the terms of the Creative
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America, ADCs were the most common cancers diag-
nosed in patients following initiation of ART [11].
However, even in resource-limited settings, NADCs
and other non-communicable diseases are of growing
concern. There is a recognized global need for im-
proved screening, diagnosis, and treatment programs
for cancer in HIV-infected populations [12-14].
Brazil represents an important upper-middle-income
country to evaluate the epidemiology of cancer occur-
ring in HIV-infected populations. Similar to high-
income countries, ART has been available in Brazil
since 1996. Brazil also has cancer registries to com-
pare rates of specific cancer types in HIV-infected
populations to rates in the general population. Import-
antly, recent studies from Brazil have indicated that
non-AIDS-defining conditions increasingly contribute
to morbidity and mortality in HIV-infected individuals
[15-19]. The epidemiology of ADCs and NADCs in
HIV-infected populations has not been described in
Brazil. It is unknown whether cancer trends in HIV-
infected populations in Brazil are similar to those in
high-income countries like the U.S. This study aimed
to compare the epidemiology and predictors of malig-
nancy in clinical cohorts of HIV patients from Rio de
Janeiro (Instituto Nacional de Infectologia Evandro
Chagas [INI]), Brazil, and Tennessee (Vanderbilt Com-
prehensive Care Clinic [VCCC]), USA, as an example
referent HIV-infected population with a diverse pa-
tient profile.Results
There were 2,925 patients (12,333.8 person-years of
follow-up) at INI and 3,927 patients (15,327.2 person-
years of follow-up) at VCCC who met inclusion criteria
for the study period. Demographic and clinical charac-
teristics of the cohorts are described in Table 1. Overall,
patients at INI were more likely to be female, slightly
younger, and have lower CD4+ lymphocyte count at
clinic entry. INI patients were more likely to report het-
erosexual risk for HIV and to enroll in care in later cal-
endar years. VCCC patients were more likely to report
injection drug use, have hepatitis C virus infection, and
report antiretroviral therapy (ART) exposure prior to
clinic enrollment. Of those patients surveyed, slightly
over half reported a history of tobacco use at each site.
Patients at both sites were followed on average for ap-
proximately three years. A high proportion of patients at
both clinics received ART during follow-up. While more
patients at INI had missing laboratory values at clinic
enrollment, the frequency of laboratory monitoring dur-
ing follow-up was similar between the two sites (data
not shown).During the study period, there were 57 incident ADCs
(37 cases of Kaposi sarcoma [KS] and 20 cases of non-
Hodgkin lymphoma [NHL]) and 45 incident NADCs di-
agnosed at INI. There were 47 incident ADCs (19 KS,
27 NHL, and 1 cervical cancer) and 82 incident NADCs
diagnosed at VCCC. The incidence of ADCs during the
study period was 4.6 per 1,000 person-years (95% confi-
dence interval [CI] 3.5-6.0) at INI and 3.3 per 1,000
person-years (95% CI 2.5-4.4) at VCCC. The incidence
of NADCs (including non-melanoma skin cancers) dur-
ing the study period was 3.6 per 1,000 person-years
(95% CI 2.7-4.9) at INI and 5.3 per 1,000 person-years
(95% CI 4.3-6.4) at VCCC. The incidence of ADCs and
NADCs by year and site are shown in Additional file 1:
Table S1 and Additional file 2: Table S2, respectively. At
INI, from 1998 to 2010, incidence of ADCs decreased
from 38.3 to 1.4 per 1,000 person-years (incidence rate
ratio [IRR] per year = 0.92 [95% CI 0.84-1.00]), which
was driven by declining incidence of KS (KS IRR per
year = 0.89 [95% CI 0.83-0.97]; NHL IRR per year = 0.96
[95% CI 0.82-1.11]). When results were restricted to
2005 to 2010, the trend of decreasing incidence was
even stronger (ADC IRR per year = 0.74 [95% CI 0.65-
0.85]). Similarly, rates of ADCs at VCCC decreased from
5.7 to 1.3 per 1,000 person-years from 1999 to 2010
(IRR per year = 0.90 [95% CI 0.85-0.96]), also due to
changing rates of KS (KS IRR per year 0.84 [95% CI
0.77-0.92]; NHL IRR per year 0.94 [95% CI 0.83-1.06]).
Like INI, this trend was strongest in the years 2005 to
2010 (ADC IRR per year = 0.75 [95% CI 0.67-0.84]). At
both sites, incidence rates of ADCs were statistically un-
changed from 1998 to 2004 (INI IRR per year = 0.82
[95% CI 0.61-1.12] and VCCC IRR per year = 0.91 [95%
CI 0.80-1.04]). Incidence of NADCs remained constant
at both sites overtime (INI IRR per year = 0.99 [95% CI
0.89-1.12]; VCCC IRR per year = 1.00 [95% CI 0.93-
1.07]). The overall incidence of KS was over two-fold
higher at INI than at VCCC during the study period (3.0
vs. 1.24 per 1,000 person-years, p < 0.01).
Rates of a number of cancers were higher than ex-
pected in respective general populations, with overall
ADC and NADC standardized incidence ratios [SIRs]
greater than one at both sites (Table 2). For both sites,
rates of KS, NHL, and anal cancer were significantly in-
creased compared to respective general populations.
Cervical cancer rates at both sites were not increased. At
INI, SIRs for lung cancer, squamous and basal cell skin
cancers, and laryngeal cancer were increased and nearly
met statistical significance. At VCCC, lung cancer and
biliary tract cancers occurred at rates significantly above
expected. Liver cancer was also associated with in-
creased risk but did not meet statistical significance at
VCCC. There was no case of liver cancer in the INI
cohort.
Table 1 Demographic and clinical characteristics of the study participants by site
INI VCCC P valuea
N = 2,925 N = 3,927
Female sex (%) 978 (33) 938 (24) <0.01
HIV transmission risk categoriesb (%) <0.01
MSM 1,035 (35) 1,569 (40)
IDU 41 (1) 374 (10)
Heterosexual males 714 (24) 456 (12)
Heterosexual females 969 (33) 835 (21)
All others 166 (6) 693 (18)
Median age in years at clinic entry [IQR] 36 [29–43] 38 [31–45] <0.01
Race (%) 0.69
White 1,552 (53) 2,103 (54)
Non-white 1,373 (47) 1,824 (46)
Median CD4+ lymphocyte count at clinic entry (cells/μL) [IQR] 287 [106–504] 325 [153–518] <0.01
Missing CD4+ lymphocyte count at clinic entry (%) 884 (30) 346 (9) <0.01
Median log10 HIV-1 RNA level at clinic entry (copies/mL) [IQR] 4.5 [3.6-5.2] 4.3 [3.1-5.0] <0.01
Missing HIV-1 RNA at clinic entry (%) 1,364 (47) 322 (8) <0.01
Median year of clinic entry [IQR] 2006 [2003–2008] 2004 [2001–2007] <0.01
Hepatitis C virus infectionc (%) 243 (9) 537 (14) <0.01
Missing hepatitis C virus infection data (%) 216 (7) 0 <0.01
Hepatitis B virus infectionc (%) 160 (6) 216 (6) 0.13
Missing hepatitis B virus infection data (%) 433 (15) 0 <0.01
History of tobacco used (%) 1,131/2,129 (53) 1,319/2,155 (61) <0.01
Missing tobacco history (%) 796 (27) 1,772 (45) <0.01
History of cancer prior to clinic entry (%) 56 (2) 105 (3) 0.04
History of ART exposure prior to clinic entry (%) 759 (26) 1,566 (40) <0.01
Median follow-up time in years [IQR] 3.5 [1.5-6.1] 3.1 (1.1-6.5) <0.01
Receipt of any ART during follow-up (%) 2,158 (74) 3,145 (80) <0.01
aP value result refers to results of Chi square test (categorical and binary variables) or Wilcoxon rank sum test (continuous variables).
bHIV transmission risk categories are mutually exclusive.
cHepatitis C and hepatitis B infection status at clinic entry for VCCC and at any point obtained during follow-up at INI, as many patients there did not have
serologic testing until after clinic entry.
dTobacco use was available from single, cross-sectional surveys completed by some patients at both clinic sites that was performed without relation to this study.
Abbreviations:
INI: Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
VCCC: Vanderbilt Comprehensive Care Clinic, Nashville, TN, USA.
MSM: men who have sex with men.
IDU: injection drug use.
ART: antiretroviral therapy.
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ADC, stratified by cohort, are shown in Table 3. In
univariable analyses, male sex, increased age at clinic
entry, low or missing CD4+ lymphocyte nadir, low time-
varying CD4+ lymphocyte count, increased log10 HIV
RNA, and cumulative follow-up time with log10 HIV
RNA ≥ 5.0 were all associated with increased risk of
ADC among patients at INI. Similar predictors were
observed at VCCC with the exception that age was not
associated with risk while race was. In multivariablemodels, male sex and low CD4+ lymphocyte count
remained statistically associated with increased risk of
ADC at both sites. At INI, increased age at clinic entry
also remained statistically significant. Cumulative follow-
up time with log10 HIV RNA ≥ 5.0 was no longer associ-
ated with ADC risk when included in a model adjusting
for CD4+ lymphocyte count.
The Cox models for predictors of first NADC, exclud-
ing squamous and basal cell skin cancers, are shown in
Table 4. In univariable analyses, at INI, only other HIV
Table 2 Standardized incidence ratios (SIRs) of AIDS- and
non-AIDS-defining cancers by study site
INI VCCC
N SIR [95% CI] N SIR [95% CI]
AIDS-defining cancers 57 24.6 [18.7-31.9] 47 17.0 [12.5-22.6]
Kaposi Sarcoma 37 269 [189–371] 19 1157 [697–1807]
Non-Hodgkin Lymphoma 20 21.2 [12.9-32.7] 27 11.4 [7.5-16.6]
Cervix 0 0 [0–3.2] 1 2.7 [0.7-14.9]
Non-AIDS-defining cancers 45 1.4 [1.1-1.9] 81 1.3 [1.0-1.7]
Oral Cavity & Pharynx 3 1.7 [0.4-5.0] 2 1.2 [0.1-4.3]
Esophagus 1 1.0 [0–5.4] 1 2.1 [0.1-11.9]
Stomach 2 1.5 [0.2-5.5] 0 0 [0–5.2]
Small Intestine 0 0 [0–47.9] 1 4.2 [0.1-23.6]
Colon & Rectum 2 1.1 [0.1-4.1] 5 1.2 [0.4-2.9]
Anus 7 62.3 [25.1-128] 9 25.0 [11.4-47.5]
Liver 0 0 [0–8.6] 3 3.7 [0.8-10.7]
Biliary Tract 0 0 [0–19.4] 2 17.6 [2.1-63.5]
Pancreas 1 2.9 [0.1-16.1] 0 0 [0–4.8]
Larynx 3 4.6 [0.9-13.3] 2 4.4 [0.5-15.7]
Lung & Bronchus 4 3.0 [0.8-7.7] 11 2.8 [1.4-5.1]
Mediastinum 1 23.0 [0.6-128] 0 0 [0–161]
Soft Tissue Sarcoma 0 0 [0–1.06] 1 2.4 [0.1-13.4]
Squamous and
basal cell skin cancers
9 1.9 [0.9-3.7] 28 Not available
Melanoma 0 0 [0–8.1] 2 0.6 [0.1-2.1]
Breast 5 1.3 [0.4-2.9] 1 0.2 [0–1.3]
Corpus Uterus 1 5.5 [0.1-30.8] 0 0 [0–7.7]
Ovary 1 3.0 [0.1-16.5] 1 3.1 [0.1-17.2]
Prostate 1 0.3 [0–1.6] 4 0.4 [0.1-1.0]
Testis 0 0 [0–16.1] 0 0 [0–4.7]
Urinary Bladder 0 0 [0–8.3] 3 2.6 [0.5-7.5]
Kidney 2 4.5 [0.5-16.2] 0 0 [0–2.2]
Brain & other CNS 0 0 [0–4.3] 0 0 [0–4.8]
Thyroid 0 0 [0–8.8] 0 0 [0–2.5]
Other Endocrine 0 0 [0–115] 1 10.0 [0.3-55.5]
Hodgkin Lymphoma 0 0 [0–12.2] 1 1.9 [0.1-10.5]
Myeloma 0 0 [0–12.3] 1 1.6 [0–9.0]
Leukemia 1 1.9 [0.1-10.7] 1 1.0 [0–5.6]
Mesothelioma 0 0 [0–181] 0 0 [0–84.9]
Other 1 1.0 [0–5.3] 1 1.7 [0–9.6]
Comparator population for INI SIRs: Belo Horizonte, MG, general population.
Comparator population for VCCC SIRs: Atlanta, GA, general population.
Abbreviations:
INI: Instituto Nacional de Infectologia Evandro Chagas, Oswaldo Cruz, Rio de
Janeiro, RJ, Brazil.
VCCC: Vanderbilt Comprehensive Care Clinic, Nashville, TN, USA.
CI: Confidence interval.
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entry were statistically associated with risk of NADCs.
Time-varying CD4+ lymphocyte count was not associ-
ated with NADC risk. At VCCC, heterosexual females,
compared with men who have sex with men, had a de-
creased risk of NADCs. Age, low CD4+ lymphocyte
nadir, and history of malignancy prior to clinic entry
were associated with increased risk of NADC at VCCC
in univariable analyses. In multivariable, only increasing
age at clinic entry remained statistically associated with
risk of incident NADC in either cohort.
Lastly, all analyses were repeated using different win-
dows of prevalent diagnoses in the sensitivity analyses
presented in Additional file 3: Table S3. The differing
prevalence windows had the greatest effect on number
of incident ADCs. However, whether cancer diagnoses
made after day zero, ten, or 30 following clinic entry
were included, results for the analyses were similar.
Discussion
This study is the first to describe the cancer epidemi-
ology in a Brazilian HIV-infected cohort with compari-
sons to that of the Brazilian general population and a US
HIV-infected cohort. Overall rates of ADCs appeared to
be decreasing and rates of NADCs remained constant, a
trend similar to that seen in the US cohort. Additionally,
risk of specific types of cancer and predictors of cancer
were similar between the two cohorts.
The decreasing rates of ADCs in both cohorts ap-
peared to be driven by declining rates of KS. In the US,
rates of KS were noted to decrease even prior to the
availability of highly active ART [2,20]. In Brazil, some
studies have also suggested a decrease in the incidence
of KS since 1996 [21]. In our study, incidence of KS was
increased in the INI cohort compared to the VCCC co-
hort. This difference may have been a result of delayed
entry into care or decreased access to ART, evidenced by
the lower median CD4+ lymphocyte count at clinic
entry and lower rate of ART receipt for INI. Studies
examining human herpesvirus-8 prevalence in Brazil and
elsewhere in Latin America have concluded a back-
ground infection risk similar to that of the U.S (0–6.6%
of blood bank donors); however prevalence of human
herpesvirus-8 in HIV-infected populations in Brazil has
not been reported [22]. That the SIR for KS was lower
for INI compared to VCCC in this study is likely a re-
flection of methodological differences in their calculation
(the VCCC SIR was calculated using KS rates prior to
the HIV epidemic and the INI SIR was calculated using
contemporary KS rates, likely influenced by a majority of
AIDS-associated cases of KS) [23]. At both sites where
active cervical cancer screening programs are present,
rates of cervical cancer were low and risk was not above ex-
pected for the respective general populations. Unlike KS
Table 3 Univariable and multivariable Cox proportional hazards models for predictors of first AIDS-defining cancer
diagnosis
INI (n = 57) VCCC (n = 47)
N# HR 95% CI P value aHR 95% CI P value N# HR 95% CI P value aHR 95% CI P value
Female sex (ref = male) 57 0.3 0.1-0.6 <0.01 0.3 0.1-0.7 <0.01 47 0.3 0.1-0.8 0.02 0.3 0.1-0.8 0.02
HIV transmission risk categories
MSM (ref) 28 1.0 24 1.0
IDU 2 1.6 0.4-6.7 0.51 6 1.1 0.4-2.6 0.90
Heterosexual males 14 0.7 0.4-1.4 0.31 3 0.4 0.1-1.4 0.17
Heterosexual females 76 0.3 0.1-0.6 <0.01 4 0.3 0.1-0.9 0.03
All others 6 1.6 0.7-3.9 0.29 10 1.2 0.6-2.5 0.64
Age at clinic entry (per 10 years) 57 1.3 1.1-1.6 0.01 1.3 1.0-1.3 0.04 47 0.9 0.7-1.1 0.30 0.8 0.6-1.1 0.16
Non-white race (ref = white) 57 1.1 0.7-1.9 0.64 47 0.5 0.3-0.9 0.03
CD4+ lymphocyte count nadir
(cells/μL)§
≥200 (ref) 10 1.0 14 1.0
<200 39 4.6 2.3-9.4 <0.01 31 3.7 1.9-7.2 <0.01
Missing 8 3.3 1.3-7.9 0.01 2 1.3 0.3-5.8 0.73
CD4+ lymphocyte count (cells/μL)§
≥200 (ref) 12 1.0 1.0 13 1.0 1.0
50-199 16 6.8 3.2-14.7 <0.01 5.8 2.6-13.0 <0.01 8 3.0 1.2-7.3 0.02 2.9 1.1-7.5 0.03
<50 14 16.5 7.2-37.6 <0.01 13.7 5.9-31.9 <0.01 13 10.6 4.9-23.2 <0.01 9.5 4.0-22.8 <0.01
Missing 15 3.8 1.8-8.0 <0.01 3.9 1.8-8.5 <0.01 13 1.3 0.6-2.9 0.52 1.4 0.6-3.4 0.39
Log10 HIV RNA level (per unit)
§ 37 1.2 1.1-1.3 <0.01 34 1.7 1.2-2.3 <0.01
Cumulative time of log10 HIV RNA≥
5.0 (per 6 months)§
57 1.5 1.1-1.9 <0.01 1.2 0.9-1.6 0.31 47 1.4 1.2-1.7 <0.01 1.1 0.8-1.4 0.55
Year of clinic enrollment 57 1.0 0.9-1.1 0.98 1.0 0.9-1.1 0.67 47 1.0 0.9-1.0 0.19 1.0 0.9-1.1 0.56
Hepatitis C virus infection 52 1.2 0.5-2.8 0.70 47 0.8 0.4-2.0 0.70
Hepatitis B virus infection 50 1.7 0.7-4.2 0.28 47 1.0 0.3-3.2 0.96
History of tobacco use 28 1.0 0.5-2.1 1.00 25 1.5 0.6-3.5 0.38
Cancer prior to clinic entry 57 0 - - 47 2.6 0.8-8.4 0.11
ART exposure prior to clinic entry 57 1.4 0.8-2.4 0.23 47 0.7 0.4-1.3 0.25
§Time-updated covariate.
#Number of events included in model.
Abbreviations:
INI: Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
VCCC: Vanderbilt Comprehensive Care Clinic, Nashville, TN, USA.
HR: hazard ratio.
aHR: adjusted hazard ratio.
CI: confidence interval.
MSM: men who have sex with men.
IDU: injection drug use.
ART: antiretroviral therapy.
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women has been most consistently reduced – and normal-
ized to that of the general population – with cervical dys-
plasia screening and treatment programs rather than access
to ART [24,25].
While rates of ADCs appeared to be decreasing at
both sites, rates of NADCs were constant. The increasingproportion of non-infectious morbidity and mortality in
HIV-infected populations has been observed in both the
US and Brazil [1,15-20,26]. In high-income countries, a
number of malignancies have been observed to occur
in HIV-infected populations at high rates, including
anal cancer, lung cancer, Hodgkin lymphoma, liver
cancer, and non-melanoma skin cancers [2]. Unlike KS
Table 4 Univariable and multivariable Cox proportional hazards models for predictors of first non-AIDS-defining cancer
diagnosis, excluding squamous and basal cell skin cancers
INI (n = 36) VCCC (n = 50)
N# HR 95% CI P value aHR 95% CI P value N# HR 95% CI P value aHR 95% CI P value
Female sex (ref = male) 36 1.3 0.6-2.5 0.46 1.4 0.7-2.7 0.31 50 0.6 0.3-1.2 0.15 0.7 0.3-1.6 0.38
HIV transmission risk categories
MSM (ref) 6 1.00 28 1.0
IDU 1 3.3 0.4-26.2 0.26 4 0.6 0.2-1.7 0.33
Heterosexual males 10 2.4 0.9-6.6 0.09 8 1.0 0.4-2.1 0.94
Heterosexual females 15 2.5 1.0-6.5 0.06 5 0.4 0.1-0.9 0.03
All others 4 6.9 2.0-24.0 <0.01 5 0.7 0.3-1.7 0.41
Age at clinic entry (per 10 years) 36 2.4 1.9-3.1 <0.01 2.4 1.9-3.1 <0.01 50 2.3 1.8-2.8 <0.01 2.2 1.7-2.7 <0.01
Non-white race (ref = white) 36 0.7 0.3-1.4 0.26 50 0.6 0.4-1.1 0.13
CD4+ lymphocyte count nadir (cells/μL)§
≥200 (ref) 14 1.0 1.0 19 1.0 1.0
<200 22 1.3 0.3-2.2 0.42 1.3 0.7-2.6 0.45 29 2.0 1.1-3.6 0.02 1.7 0.9-3.1 0.11
Missing 0 - - - - - 2 1.4 0.3-5.9 0.67 1.06 0.2-4.6 0.94
CD4+ lymphocyte count (cells/μL)§
≥500 (ref) 12 1.0 11 1.0
350-499 10 1.5 0.7-3.6 0.33 3 0.5 0.1-1.9 0.33
<350 11 1.3 0.6-2.9 0.56 19 1.9 0.9-3.9 0.10
Missing 3 0.4 0.1-1.6 0.20 17 0.8 0.4-1.7 0.57
Log10 HIV-1 RNA level (per unit)
§ 27 0.6 0.4-1.1 0.08 33 1.0 0.7-1.3 0.83
Cumulative time of log10 HIV RNA≥
5.0 (per 6 months)§
36 0.8 0.6-1.2 0.31 50 0.9 0.7-1.2 0.52
Year of clinic enrollment 36 1.0 0.9-1.1 0.84 1.0 0.9-1.1 0.96 50 1.0 0.9-1.1 1.0 1.0 0.9-1.1 0.77
Hepatitis C virus infection 34 2.0 0.9-4.7 0.10 50 1.3 0.7-2.7 0.41
Hepatitis B virus infection 32 0.5 0.1-3.5 0.47 50 1.2 0.4-3.4 0.68
History of tobacco use 16 1.1 0.4-3.0 0.83 29 1.6 0.7-3.8 0.25
Cancer prior to clinic entry 36 3.7 0.9-15.6 0.07 3.1 0.8-12.8 0.12 50 4.3 1.7-10.9 <0.01 2.2 0.8-6.1 0.14
ART exposure prior to clinic entry 36 1.5 0.8-3.0 0.23 50 1.6 0.9-2.8 0.09
§Time-updated covariate.
#Number of events included in model.
Abbreviations:
INI: Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
VCCC: Vanderbilt Comprehensive Care Clinic, Nashville, TN, USA.
HR: hazard ratio.
aHR: adjusted hazard ratio.
CI: confidence interval.
MSM: men who have sex with men.
IDU: injection drug use.
ART: antiretroviral therapy.
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been associated with degree of immunosuppression [5,27].
Among the NADCs diagnosed in the INI, risk of anal can-
cer was more than 60-fold greater than in the general
population, likely related to men who have sex with men
and high rates of human papillomavirus infection. In 2010,
INI began screening for anal dysplasia; however, only two
of the seven cases of anal cancer in this study were diag-
nosed that year. In 2014, anal dysplasia screening was also
implemented at VCCC. These screening programs aim toreduce the excess anal cancer observed at both locations.
Finally, rates of laryngeal cancer and lung cancer were also
increased in the INI cohort, though not quite meeting
statistical significance, and were likely related to the high
tobacco use reported in the cohort. These cancers have also
been observed to occur at increased rates in HIV-infected
populations in the US [5,28,29]. Smoking cessation pro-
grams for harm reduction due to tobacco-related cancers is
needed in both countries as the HIV-infected populations
continue to age.
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yielded remarkably similar results for both cohorts. For
both cohorts, female sex was associated with decreased
risk of ADCs. This effect was likely due to increased risk
of human herpesvirus-8 infection and KS among men
who have sex with men, a pattern observed in previous
studies from the U.S. and Brazil [21,30]. Among the HIV
disease markers that we examined, time-varying CD4+
lymphocyte count remained statistically associated with
risk of ADC in multivariable models for both sites. In
the multivariable model for INI, increased age at clinic
entry was also associated with a small but significant
increased risk of ADC. Previous studies have demon-
strated an association between human herpesvirus-8
prevalence and age, which could explain this finding
[31]. Further study of human herpesvirus-8 epidemi-
ology among HIV-infected individuals in Brazil is needed
to explore this relationship.
In examination of NADCs, age was the only significant
predictor of risk in multivariable analyses for both co-
horts. Unlike the strong association for risk of KS and
NHL, CD4+ lymphocyte count has not been consistently
associated with risk of NADCs [4,8,32-34]. In our study,
risk of NADC was not associated with time-varying CD4+
lymphocyte count in univariable analysis at either site.
Among patients at VCCC, low CD4+ lymphocyte nadir
(<200 cells/μL) was associated with a two-fold increased
risk of NADCs in univariable analysis but was not statisti-
cally significant in multivariable analyses adjusting for age.
Our study has a number of limitations. We aimed to
describe incidence of cancers at both sites and sought to
avoid misclassification of prevalent cases by excluding
diagnoses occurring the first ten days of clinic follow-up.
It is possible that some of the cancers included in this
study reflect prevalent rather than incident cases; how-
ever, our analyses using a longer window (30 days)
yielded similar results. Our study of incidence trends
also failed to show a statistically significant decline in
ADCs during the early years (1998–2004) of the study
period. This may have been due to the smaller amount
of person-time contributed during that time or delayed
uptake of ART. Another important limitation occurred
in the calculation of SIRs for INI. Limited by data avail-
able through the regional cancer registries, we could
not perform year-adjusted analyses as part of the SIR
calculation, having incidence data available only for
2000–2003. However, while these limitations are ac-
knowledged, these analyses reflect the first assessment
of cancer risk among a HIV-infected cohort compared
to risk in the Brazilian general population. The similar-
ity of the results with those of the US cohort suggests
the conclusions drawn from the SIRs are reasonable
and likely reflect valid epidemiologic patterns in Brazil.
Lastly, due to the small number of events in bothcohorts, cancers were assessed in the Cox models as
ADCs and NADCs, rather than as individual cancer
types. By doing so, cancers without a known association
with HIV or other infections (such as breast and
prostate cancer) may have limited our ability to detect
risk differences conferred by immunodeficiency, HIV-1
RNA, or co-infection by hepatitis viruses. Grouping
NADCs into subgroups, including “infectious” and
“non-infectious,” may still result in false epidemiologic
conclusions and was, therefore, not performed [35].
Even with treating the cancers in groupings of ADCs
and NADCs, the small number of events limited our
power to detect statistical differences in important
predictors (such as immunodeficiency). Our ability to
examine predictors of cancers was also limited by the
partial availability of tobacco history for both cohorts,
an important risk factor for NADCs. Given the stronger
association of the effects of ART (immune status and
HIV-1 RNA) rather than ART itself, our Cox models
did not include time-varying ART as a predictor of
cancer. Thus, we cannot assess if differences in ART
regimens either within or between cohorts affected risk
of ADCs or NADCs.
In this comparative study of Brazilian and U.S. co-
horts, we found similar trends in cancer incidence, risk
compared to respective general populations, and predic-
tors of malignancy between the two cohorts. As an
upper-middle-income country, Brazil is unique in its his-
tory of early availability of ART. Recent studies of causes
of death among HIV-infected persons in Brazil also have
indicated an increasing proportion of non-infectious
mortality, similar to that of high-income countries. Fur-
ther study is needed to examine the ongoing excess risk
of KS in Brazil despite available ART. Development of
screening and prevention programs for malignancy is
needed in both countries.
Conclusions
This study is the first to examine thoroughly epidemio-
logic trends of AIDS-defining cancers and non-AIDS-
defining cancers in an HIV-infected population in Brazil,
with a referent US HIV-infected population for compari-
son. Similar to trends observed in the US setting, the
cancer burden in the HIV-infected population in Brazil
has shifted from ADCs to increasingly NADCs. A num-
ber of NADCs occurred at rates higher than expected in
the general Brazilian population. Ongoing cancer screen-
ing and prevention, including early availability of ART, is
need in both countries.
Methods
This study included adult patients (age ≥ 18 years) of the
HIV clinics of the Instituto Nacional de Infectologia
Evandro Chagas (INI) of Fundação Oswaldo Cruz in Rio
Castilho et al. Infectious Agents and Cancer 2015, 10:4 Page 8 of 10
http://www.infectagentscancer.com/content/10/1/4de Janeiro and the Vanderbilt Comprehensive Care
Clinic (VCCC) in Nashville. Both single-site cohorts,
these clinics provide comprehensive HIV-specialty and
primary care to HIV-infected patients. At both clinics,
patients are seen routinely every 3 to 6 months for
follow-up care. Data for this study were abstracted
and validated from medical records at each site. The
study was approved by the Comitê de Ética em Pesquisa
of INI and by the Vanderbilt University Institutional
Review Board.
This retrospective analysis included only new patients
who enrolled in care between January 1, 1998, and De-
cember 31, 2010. For inclusion, patients must have com-
pleted a minimum of 60 days of follow-up (INI) or two
clinic visits within the first year of clinic entry (VCCC).
Patient follow-up time was censored at death, December
31, 2010, or at the last clinic visit when death occurred
more than one year after the last clinic visit or if the last
clinic visit was more than one year before the end of the
study period (December 31, 2010). Demographic and
clinical characteristics of the cohorts were compared
using Chi square and Wilcoxon rank sum tests.
The primary outcomes of interest were incident ADCs
and NADCs. ADCs included Kaposi sarcoma (KS), non-
Hodgkin lymphoma (NHL), and cervical cancer. NADCs
included all other cancers. To exclude prevalent cases,
cancers diagnosed during the first ten days of clinic
follow-up were excluded. Sensitivity analyses with only
the exclusion of cancers diagnosed the day of clinic entry
and with the exclusion of cancers diagnosed during the
first 30 days of follow-up were performed.
Trends in cancer incidence were examined by Poisson
regression. Incidence of ADCs and NADCs were calcu-
lated as the number of malignancies divided by the total
person-time of follow-up of patients enrolled in care
each calendar year. Trends were examined by incidence
rate ratios (IRR) per year.
To compare rates of individual cancer types with those
of the respective general populations, standardized inci-
dence ratios (SIRs) were calculated by dividing the ob-
served by the expected number of cases [36]. For INI, data
from Instituto Nacional do Câncer and Instituto Brasileiro
de Geografia e Estatística were used to calculate age- and
sex-adjusted rates of each cancer type using the 2000–
2003 Belo Horizonte registry, as data for Rio de Janeiro
are not collected (available at http://www2.inca.gov.br and
http://www.ibge.gov.br). Belo Horizonte was selected be-
cause, like Rio de Janeiro, it is a capital city of a southeast-
ern state in Brazil. For VCCC, data from Surveillance
Epidemiology and End Results (SEER) were used to calcu-
late age-, sex-, race-, and year-adjusted rates of each can-
cer type using the Atlanta registry, as data for Nashville
are not collected (available at http://seer.cancer.gov).
Given the strong association of KS with HIV infection,expected KS cases were calculated using the age- and
sex-adjusted rates from SEER for 1975–1979 [23]. At-
lanta was selected because, like Nashville, it is a cap-
ital city of a southeastern state in the US. SEER does
not collect data on squamous and basal cell skin can-
cers so SIRs for these cancers could not be calculated
for the VCCC cohort.
Stratified by cohort, Cox proportional hazards models
were used to examine predictors of first ADCs and
NADCs, excluding squamous and basal cell skin cancers.
Patient follow-up time was censored after first cancer
event. Baseline demographic and clinical variables were
included. Tobacco use data, dichotomized into ever or
never users, were from cross-sectional surveys com-
pleted previously by a subset of patients at each clinic
site. Time-updated CD4+ lymphocyte count (cells/μL),
log10 HIV RNA (copies/mL), CD4+ lymphocyte nadir
(cells/μL), and cumulative follow-up time with recorded
log10 HIV RNA ≥ 5.0 were also included (described
below). Multivariable models included a selection of var-
iables based upon physiologic relevance and the number
of events to avoid over-fitting.
Time-updated CD4+ lymphocyte count and log10 HIV
RNA were created by dividing follow-up time into inter-
vals based upon laboratory events. Laboratory values
were carried forward until the next available laboratory
results or censoring. When intervals were more than six
months, time was divided such that time beyond six
months after a laboratory event was associated with
missing values until the next laboratory event or
censoring occurred. Time-updated CD4+ lymphocyte
count nadir was recorded as the lowest absolute CD4+
lymphocyte count available. Time-updated cumulative
follow-up time with log10 HIV RNA ≥ 5.0 was recorded
as the total amount of follow-up time with HIV RNA
level ≥ 100,000 copies/mL. Patients with missing data
were labeled as no documented time with log10 HIV
RNA ≥ 5.0.
All reported P values are two-sided. All analyses were
performed using Stata 12.1 (Stata Corporation, College
Station, Texas, USA).
Consent
Data for this study was obtained systematically from
medical records of observational, clinic-based research
cohorts. Patients at INI provide written informed con-
sent for prior to inclusion in the observational cohort.
Observational data from patients at VCCC are gathered
retrospectively and, as written informed consent is not
feasible for all patients, stored and analyzed removed of
all personal identifiers to protect patient privacy. The
study was approved by the Comitê de Ética em Pesquisa
of INI and by the Vanderbilt University Institutional
Review Board.
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